Evidence map›Paper›PMID 36130753›Full record

ArticleBMJ open2022

Remission of type 2 diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction among young adults: the RESET for REMISSION randomised controlled trial protocol.

Kaberi Dasgupta, Normand Boulé, Joseph Henson, Stéphanie Chevalier, Emma Redman, Deborah Chan, Matthew McCarthy, Julia Champagne, Frank Arsenyadis, Jordan Rees and 15 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Designing a regional clinical service for people with early-onset type 2 diabetes in England.Diabetic medicine : a journal of the British Diabetic Association · 2025
    Article
  7. Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target.Journal of cardiovascular development and disease · 2023
    Review
  8. Diabetic cardiomyopathy: an educational review.The British journal of cardiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 2 countries.

Kaberi Dasgupta *Department of Medicine, McGill University and Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada kaberi.dasgupta@mcgill.ca ty20@leicester.ac.uk.ORCID 0000-0002-2447-3553
Normand BouléFaculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.
Joseph HensonDiabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Stéphanie ChevalierSchool of Human Nutrition, McGill University, Montreal, Quebec, Canada.ORCID 0000-0002-8497-1570
Emma RedmanLeicester Diabetes Centre, University Hospitals of Leicester NHS Trust and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Deborah ChanCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0001-5006-1651
Matthew McCarthyDiabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Julia ChampagneCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Frank ArsenyadisDiabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Jordan ReesFaculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.
Deborah Da CostaDepartment of Medicine, McGill University and Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Edward GreggSchool of Public Health, Imperial College London, London, UK.ORCID 0000-0003-2381-6822
Roseanne YeungDivision of Endocrinology & Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Michelle HadjiconstantinouDiabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Abhishek DattaniDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.ORCID 0000-0001-7405-6056
Matthias G FriedrichCourtois Cardiovascular Signature Centre, McGill University Health Centre and Departments of Medicine and Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester and NIHR Applied Research Collaboration - East Midlands (ARC-EM), University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Elham RahmeDepartment of Medicine, McGill University and Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.ORCID 0000-0002-4168-4993
Isabel FortierDepartment of Medicine, McGill University and Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Carla M PradoDepartment of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.
Mark ShermanDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Richard B ThompsonDepartment of Biomedical Engineering, University of Alberta, Edmonton, Alberta, Canada.
Melanie J DaviesDiabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.
Gerry P McCannDepartment of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK.ORCID 0000-0002-5542-8448
Thomas Yates *Diabetes Research Centre, University of Leicester and NIHR Leicester Biomedical Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK kaberi.dasgupta@mcgill.ca ty20@leicester.ac.uk.
University of Leicester · GBMcGill University Health Centre · CAUniversity of Alberta · CAMcGill University · CAImperial College London · GB

Funding

Department of HealthMedical Research Council MR/T031816/1Medical Research Council MR/V020536/1
6 · The paper itself

Abstract

introductionType 2 diabetes mellitus (T2DM) onset before 40 years of age has a magnified lifetime risk of cardiovascular disease. Diastolic dysfunction is its earliest cardiac manifestation. Low energy diets incorporating meal replacement products can induce diabetes remission, but do not lead to improved diastolic function, unlike supervised exercise interventions. We are examining the impact of a combined low energy diet and supervised exercise intervention on T2DM remission, with peak early diastolic strain rate, a sensitive MRI-based measure, as a key secondary outcome. METHODS AND ANALYSIS: This prospective, randomised, two-arm, open-label, blinded-endpoint efficacy trial is being conducted in Montreal, Edmonton and Leicester. We are enrolling 100 persons 18-45 years of age within 6 years' T2DM diagnosis, not on insulin therapy, and with obesity. During the intensive phase (12 weeks), active intervention participants adopt an 800-900 kcal/day low energy diet combining meal replacement products with some food, and receive supervised exercise training (aerobic and resistance), three times weekly. The maintenance phase (12 weeks) focuses on sustaining any weight loss and exercise practices achieved during the intensive phase; products and exercise supervision are tapered but reinstituted, as applicable, with weight regain and/or exercise reduction. The control arm receives standard care. The primary outcome is T2DM remission, (haemoglobin A1c of less than 6.5% at 24 weeks, without use of glucose-lowering medications during maintenance). Analysis of remission will be by intention to treat with stratified Fisher's exact test statistics. ETHICS AND DISSEMINATION: The trial is approved in Leicester (East Midlands - Nottingham Research Ethics Committee (21/EM/0026)), Montreal (McGill University Health Centre Research Ethics Board (RESET for remission/2021-7148)) and Edmonton (University of Alberta Health Research Ethics Board (Pro00101088). Findings will be shared widely (publications, presentations, press releases, social media platforms) and will inform an effectiveness trial. TRIAL REGISTRATION NUMBER: ISRCTN15487120.

Indexed as

Diabetes Mellitus, Type 2ChildExerciseGlucoseGlycated HemoglobinHumansInsulinProspective StudiesRandomized Controlled Trials as TopicYoung AdultGlucoseGlycated HemoglobinInsulinCARDIOLOGYDIABETES & ENDOCRINOLOGYNUTRITION & DIETETICS

Identifiers

PMID36130753
PMCPMC9494595
OpenAlexW4296793975

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.